Opko Health Inc (OPK)

[JDUB]

Barrington Stick to Their Buy Rating for Opko Health Inc
8 hours ago (Sep 15, 2020 05:45PM ET)


Barrington analyst Michael Petusky maintained a Buy rating on Opko Health (NASDAQ:OPK) Inc on Tuesday, setting a price target of $7, which is approximately 120.82% above the present share price of $3.17.

Petusky expects Opko Health Inc to post earnings per share (EPS) of $0.05 for the third quarter of 2020.

The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Opko Health, with an average price target of $8.
The analysts price targets range from a high of $10 to a low of $6.5.

In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $301.21 million and a net profit of $28.29 million. The company's market cap is $2.12 billion.

According to TipRanks.com, Barrington analyst Michael Petusky is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 4.0% and a 48.62% success rate.

OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Barrington Stick to Their Buy Rating for Opko Health Inc

Add a Comment